Viking Therapeutics (VKTX) Gains from Sales and Divestitures (2016 - 2025)
Historic Gains from Sales and Divestitures for Viking Therapeutics (VKTX) over the last 11 years, with Q3 2025 value amounting to $744017.0.
- Viking Therapeutics' Gains from Sales and Divestitures fell 5202.99% to $744017.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $744017.0, marking a year-over-year decrease of 5202.99%. This contributed to the annual value of $1.6 million for FY2024, which is 9755.36% up from last year.
- Latest data reveals that Viking Therapeutics reported Gains from Sales and Divestitures of $744017.0 as of Q3 2025, which was down 5202.99% from $668015.0 recorded in Q2 2025.
- In the past 5 years, Viking Therapeutics' Gains from Sales and Divestitures ranged from a high of $1.6 million in Q3 2024 and a low of $192229.0 during Q1 2021
- Its 5-year average for Gains from Sales and Divestitures is $652866.8, with a median of $668015.0 in 2025.
- Per our database at Business Quant, Viking Therapeutics' Gains from Sales and Divestitures surged by 27672.02% in 2021 and then crashed by 5202.99% in 2025.
- Over the past 5 years, Viking Therapeutics' Gains from Sales and Divestitures (Quarter) stood at $270063.0 in 2021, then skyrocketed by 51.66% to $409569.0 in 2022, then soared by 91.69% to $785105.0 in 2023, then skyrocketed by 97.55% to $1.6 million in 2024, then plummeted by 52.03% to $744017.0 in 2025.
- Its Gains from Sales and Divestitures stands at $744017.0 for Q3 2025, versus $668015.0 for Q2 2025 and $668015.0 for Q1 2025.